ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Purchased by Calamos Advisors LLC

Calamos Advisors LLC raised its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 122.5% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 250,185 shares of the biotechnology company’s stock after acquiring an additional 137,749 shares during the quarter. Calamos Advisors LLC’s holdings in ADMA Biologics were worth $1,131,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ADMA. Arizona State Retirement System boosted its stake in shares of ADMA Biologics by 4.9% in the fourth quarter. Arizona State Retirement System now owns 59,728 shares of the biotechnology company’s stock worth $270,000 after acquiring an additional 2,769 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in ADMA Biologics by 10.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 31,829 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 2,986 shares during the last quarter. Cambridge Investment Research Advisors Inc. grew its holdings in shares of ADMA Biologics by 31.3% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 15,000 shares of the biotechnology company’s stock worth $54,000 after buying an additional 3,572 shares in the last quarter. Swiss National Bank raised its position in shares of ADMA Biologics by 1.0% in the third quarter. Swiss National Bank now owns 439,800 shares of the biotechnology company’s stock valued at $1,574,000 after buying an additional 4,300 shares during the last quarter. Finally, Metropolitan Life Insurance Co NY raised its position in shares of ADMA Biologics by 61.5% in the fourth quarter. Metropolitan Life Insurance Co NY now owns 11,565 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 4,403 shares during the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Price Performance

Shares of ADMA stock opened at $6.27 on Monday. The company has a debt-to-equity ratio of 1.04, a current ratio of 5.16 and a quick ratio of 1.69. The company has a market capitalization of $1.43 billion, a PE ratio of -48.23 and a beta of 0.46. The firm’s 50-day moving average is $5.96 and its two-hundred day moving average is $4.78. ADMA Biologics, Inc. has a 12 month low of $3.06 and a 12 month high of $6.76.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.02 by $0.02. ADMA Biologics had a negative net margin of 10.94% and a positive return on equity of 0.49%. The firm had revenue of $73.90 million for the quarter, compared to analyst estimates of $73.50 million. Analysts predict that ADMA Biologics, Inc. will post 0.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Mizuho boosted their price target on shares of ADMA Biologics from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. HC Wainwright restated a “buy” rating and issued a $7.50 price target (up from $6.00) on shares of ADMA Biologics in a research report on Tuesday, March 26th. Finally, Cantor Fitzgerald lifted their price objective on ADMA Biologics from $6.50 to $8.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $7.88.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Steve Elms sold 49,887 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $6.01, for a total value of $299,820.87. Following the transaction, the director now owns 2,527,500 shares of the company’s stock, valued at $15,190,275. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 639,895 shares of company stock worth $3,927,169 over the last quarter. 6.00% of the stock is currently owned by company insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.